Table 2.
Experimental Groups | HR During Long-Term ETA Antagonist Treatment | ||||
---|---|---|---|---|---|
24 h | 48 h | 72 h | 120 h | 144 h | |
Control | 367 ± 6 | 362 ± 6 | 358 ± 6 | 363 ± 6 | 363 ± 6 |
C + BQ610 (12 ng/h) | 364 ± 5 | 361 ± 5 | 367 ± 9 | 355 ± 10 | 348 ± 7 |
C + BQ610 (24 ng/h) | 357 ± 7 | 356 ± 8 | 345 ± 3 | 364 ± 5 | 358 ± 5 |
DOCA-salt | 347 ± 7 | 359 ± 9 | 349 ± 11 | 366 ± 9 | 356 ± 8 |
DOCA + BQ610 (12 ng/h) | 356 ± 6 | 365 ± 9 | 348 ± 8 | 360 ± 7 | 349 ± 8 |
DOCA + BQ610 (24 ng/h) | 359 ± 11 | 364 ± 8 | 351 ± 7 | 371 ± 9 | 359 ± 10 |